Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 11/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7038613 | 0.90 | ALDH1A1 (0.41) | PARP1ALDH1A1CYP3A4TSHRHSD17B10 | |
| SCHEMBL29187807 | 0.83 | PARP1 (0.47) | PARP1ADRA1A | |
| SCHEMBL5464408 | 0.81 | PARP1 (0.44) | PARP1ALDH1A1ADRA1A | |
| SCHEMBL10911484 | 0.80 | KDM4E (0.46) | PARP1ALDH1A1HSD17B10TDP1ADRA1A | |
| SCHEMBL30826400 | 0.78 | PARP1 (0.43) | PARP1ADRA1A | |
| SCHEMBL29187798 | 0.78 | PARP1 (0.43) | PARP1ADRA1A | |
| SCHEMBL10692184 | 0.75 | PARP1 (0.41) | PARP1ALDH1A1HSD17B10TDP1 | |
| SCHEMBL19337381 | 0.74 | ADRA1A (0.53) | PARP1ALDH1A1CYP3A4TSHRHSD17B10 | |
| SCHEMBL16372577 | 0.74 | ADRA1A (0.53) | PARP1ALDH1A1CYP3A4TSHRHSD17B10 | |
| SCHEMBL10692188 | 0.74 | PARP1 (0.40) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1413286-B1 | Dyeing composition comprising at least one heterocyclic oxidation base and at least one substituted 2,3-diaminopyridine as a coupling agent | OREAL (FR) | 2009-04-22 | — | — | EP | claimed |
| WO-2007071688-A1 | COMPOSITION FOR DYEING KERATIN FIBRES WITH A TETRAAZAPENTAMETHINE CATIONIC DIRECT DYE, A PARTICULAR OXIDATION BASE AND A COUPLER | L'ORÉAL (FR) | 2007-06-28 | — | — | WO | claimed |
| EP-1413286-A1 | Dyeing composition comprising at least one heterocyclic oxidation base and at least one substituted 2,3-diaminopyridine as a coupling agent | L'OREAL (FR) | 2004-04-28 | — | — | EP | claimed |
| US-20200276102-A1 | SPECIFIC 7-AMINO-1,2,3,4-TETRAHYDROQUINOLINES, METHOD, AND COMPOSITION | L'OREAL (FR) | 2020-09-03 | — | — | US | disclosed |
| EP-2182914-B1 | COMPOSITION OXIDATION COLOURING OF KERATINIC FIBRES, CONTAINING A CATIONIC CELLULOSE ETHER, A METASILICATE AND OXIDATION DYES, METHOD FOR OXIDATION COLOURING AND USES THEREOF | L'ORÉAL (FR) | 2017-11-08 | — | — | EP | disclosed |
| EP-2175830-B1 | COMPOSITION FOR OXIDATION DYEING KERATIN FIBRES COMPRISING A CATIONIC CELLULOSE ETHER, A WEAKLY OXYETHYLENATED SORBITAN FATTY ACID ESTER AND OXIDATION DYES | ORÉAL L (FR) | 2015-09-30 | — | — | EP | disclosed |
| US-8043385-B2 | Composition oxidation colouring of keratinic fibres, containing a cationic cellulose ether, a metasilicate and oxidation dyes, method for oxidation colouring and uses thereof | L'OREAL S.A. (FR) | 2011-10-25 | — | — | US | disclosed |
| US-8002847-B2 | Composition for oxidation dyeing keratin fibres comprising a cationic cellulose ether, a weakly oxyethylenated sorbitan fatty acid ester and oxidation dyes | L 'OREAL S.A. (FR) | 2011-08-23 | — | — | US | disclosed |
| US-20100263138-A1 | COMPOSITION OXIDATION COLOURING OF KERATINIC FIBRES, CONTAINING A CATIONIC CELLULOSE ETHER, A METASILICATE AND OXIDATION DYES, METHOD FOR OXIDATION COLOURING AND USES THEREOF | L'OREAL S.A. (FR) | 2010-10-21 | — | — | US | disclosed |
| EP-2182914-A2 | COMPOSITION OXIDATION COLOURING OF KERATINIC FIBRES, CONTAINING A CATIONIC CELLULOSE ETHER, A METASILICATE AND OXIDATION DYES, METHOD FOR OXIDATION COLOURING AND USES THEREOF | L'Oreal (FR) | 2010-05-12 | — | — | EP | disclosed |
| EP-2175830-A2 | COMPOSITION FOR OXIDATION DYEING KERATIN FIBRES COMPRISING A CATIONIC CELLULOSE ETHER, A WEAKLY OXYETHYLENATED SORBITAN FATTY ACID ESTER AND OXIDATION DYES | L'Oreal (FR) | 2010-04-21 | — | — | EP | disclosed |
| EP-1413286-B1 | Dyeing composition comprising at least one heterocyclic oxidation base and at least one substituted 2,3-diaminopyridine as a coupling agent | OREAL (FR) | 2009-04-22 | — | — | EP | disclosed |
| WO-2009019383-A2 | COMPOSITION OXIDATION COLOURING OF KERATINIC FIBRES, CONTAINING A CATIONIC CELLULOSE ETHER, A METASILICATE AND OXIDATION DYES, METHOD FOR OXIDATION COLOURING AND USES THEREOF | L'OREAL (FR) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009016061-A2 | COMPOSITION FOR OXIDATION DYEING KERATIN FIBRES COMPRISING A CATIONIC CELLULOSE ETHER, A WEAKLY OXYETHYLENATED SORBITAN FATTY ACID ESTER AND OXIDATION DYES | L'OREAL (FR) | 2009-02-05 | — | — | WO | disclosed |
| WO-2007071688-A1 | COMPOSITION FOR DYEING KERATIN FIBRES WITH A TETRAAZAPENTAMETHINE CATIONIC DIRECT DYE, A PARTICULAR OXIDATION BASE AND A COUPLER | L'ORÉAL (FR) | 2007-06-28 | — | — | WO | disclosed |
| EP-1459732-A1 | Dye composition comprising at least one heterocyclic oxidation base and at least one 2,3,5-triaminopyridine as coupler | L'OREAL (FR) | 2004-09-22 | — | — | EP | disclosed |
| EP-1413286-A1 | Dyeing composition comprising at least one heterocyclic oxidation base and at least one substituted 2,3-diaminopyridine as a coupling agent | L'OREAL (FR) | 2004-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200276102-A1 | SPECIFIC 7-AMINO-1,2,3,4-TETRAHYDROQUINOLINES, METHOD, AND COMPOSITION | KRT18, TUBA1C, TPM4 | PARP1 938/4885ALDH1A1 917/4885CYP3A4 1687/4885 |
| US-20100263138-A1 | COMPOSITION OXIDATION COLOURING OF KERATINIC FIBRES, CONTAINING A CATIONIC CELLULOSE ETHER, A METASILICATE AND OXIDATION DYES, METHOD FOR OXIDATION COLOURING AND USES THEREOF | KRT18, TUBB3, VIM | PARP1 2891/4885ALDH1A1 1691/4885CYP3A4 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.